Trial intelligence / Profile preview

RWJ333369 adjunctive therapy for partial-onset seizures

2006-003941-17Phase 3Completed

Sponsor
Janssen Pharmaceutical
Start
Sep 2006
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, randomised, double-blind trial in epilepsy comparing RWJ333369 adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Percent reduction in seizure frequency. Started Sep 2006; status: completed.

02

Drugs

carisbamate
03

Conditions

epilepsy

Beyond the preview

Go deeper on 2006-003941-17.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2006-003941-17.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call